Kantarjian et al53 assessed the efficacy and safety of dasatinib, as in contrast with imatinib, for the initial-line remedy of CML-CP. Five hundred and nineteen patients with newly diagnosed CML-CP had been randomly assigned to acquire dasatinib at a dose of 100 mg the moment each day (259 sufferers) or https://nikose196vzd9.tusblogos.com/profile